Victor Vinci, PhD is currently Director of Bioprocess Operations at Eli Lilly and Company in Indianapolis, Indiana. He is responsible for process operations focused on bringing new protein therapeutics to market by producing bulk drug substance for clinical trials. His responsibilities include operations in a 200,000 sq ft cGMP bulk process facility, engineering and technical services teams, tech transfer, and improving platform operations for bioproducts. He served as the lead for the Lilly team involved with the CMC Biotech Working Group (industry consortium) which has finished a QbD case study for a monoclonal antibody (Mab). Prior to his current role, he was a scientist and group leader in process development at Eli Lilly for five years. He began his career at Merck where he was a scientist and section head in Manufacturing Science and Technology (MS&T). Vinci received his doctorate in Microbiology from The Ohio State University in 1988.